Group 1: Market Performance and Technical Advantages - The company is recognized as a leading provider of pharmaceutical logistics automation, information technology, and mobile healthcare solutions, with significant advantages in software and hardware system integration, data processing, equipment management, automated dispensing, and robotics technology [1] - The company plans to enhance R&D investment to meet the growing demands of the overseas market and drive product innovation and technological upgrades [1] Group 2: Dividend Policy and Shareholder Returns - For the fiscal year 2023, the company plans to distribute a cash dividend of 1.00 yuan (tax included) for every 10 shares, totaling 13,600,000.00 yuan (tax included), which represents 22.67% of the net profit attributable to shareholders [2] - The company aims to establish a robust shareholder return mechanism to protect the rights of minority shareholders and create stable return expectations [2] Group 3: Industry Policy Trends - The healthcare sector is experiencing significant impacts from policy reforms, with a focus on promoting high-quality development in public hospitals, which is expected to enhance market conditions [2] - The company will actively respond to the policy environment, adjust its business strategies, strengthen product R&D, expand overseas markets, and optimize production and management efficiency [2]

证券代码：605186 证券简称：健麾信息 公告编号：2024-027 上海健麾信息技术股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2023 年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2024 年 6 月 27 日 13 点 30 分 召开地点：上海市松江区中辰路 518 号 A 栋会议室 (五)网络投票的系统、起止日期和投票时间。 股东大会召开日期：2024年6月27日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运 作》等有关规定执行。 (七)涉及公开征集股东投票权 不涉及 二、 会议审议事项 本次股东大 ...

证券代码：605186 证券简称：健麾信息 公告编号：2024-026 上海健麾信息技术股份有限公司 关于召开 2023 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 说明会类型 会议召开时间：2024 年 06 月 13 日(星期四) 下午 15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址： 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 06 月 05 日(星期三) 至 06 月 12 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 stock@g-healthy.com 进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 本次投资者说明会以网络互动形式召开，公司将针对 2023 年度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在 信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2024 年 06 月 13 日 下午 15 ...

证券简称：健麾信息 证券代码：605186 公告编号：2024-025 交易标的：美团买药现有运营的智慧零售项目资产。 成交金额：13,506,000元人民币 本次购买资产事项无需公司董事会及股东大会审议。 上海健麾信息技术股份有限公司 关于签署"智慧药店"战略合作协议的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 责任。 重要内容提示： 2024年2月9日，上海健麾信息技术股份有限公司（以下简称"公司"、 "甲方"、"健麾信息"）与北京三快在线科技有限公司（以下简称"乙 方"、"三快在线"或"美团买药"）签署了《关于"智慧药店"之战略 合作协议》。基于前述战略合作协议约定，双方签署了《关于"智慧零售 项目"业务收购协议》。近日，双方就上述交易事项，已完成资产交割程 序。 本次购买资产事项不构成关联交易，也不构成《上市公司重大资产重组 管理办法》规定的重大资产重组，交易实施不存在重大法律障碍。 一、合同签署情况 2024年2月9日，健麾信息与美团买药双方签署了《关于"智慧药店"之战略合 作协议》。具体内容详见公司于 ...

Revenue and Profitability - Revenue for Q1 2024 was CNY 35,633,143.76, a decrease of 41.85% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 5,242,315.57, down 47.28% year-over-year[11] - Basic earnings per share decreased by 42.86% to CNY 0.04[6] - Total operating revenue for Q1 2024 was ¥35,633,143.76, a decrease of 41.9% compared to ¥61,275,234.89 in Q1 2023[20] - Net profit for Q1 2024 was ¥2,357,351.02, a decline of 71.5% from ¥8,258,699.04 in Q1 2023[21] - The company’s total comprehensive income for Q1 2024 was ¥2,357,351.02, significantly lower than ¥8,258,699.04 in Q1 2023[22] Cash Flow and Liquidity - Operating cash flow was negative at CNY -64,638,160.26, indicating cash outflow from operations[5] - Cash flow from operating activities for Q1 2024 was -¥64,638,160.26, worsening from -¥46,915,420.31 in Q1 2023[26] - Cash received from sales and services in Q1 2024 was ¥48,022,274.36, down from ¥65,772,336.09 in Q1 2023[25] - Total cash inflow from financing activities was $18.5 million, compared to $25 million in the previous period, reflecting a decrease of 26%[27] - Net cash flow from financing activities was $7.94 million, down from $24.74 million, indicating a decline of approximately 68%[27] - The beginning cash and cash equivalents balance was $233.7 million, down from $334.1 million, representing a decline of 30%[27] - The ending cash and cash equivalents balance stood at $153.16 million, significantly lower than the previous period's $270.99 million[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,314,232,411.33, a slight decrease of 0.19% from the previous year[6] - As of March 31, 2024, the total assets amounted to CNY 1,314,232,411.33, a slight decrease from CNY 1,316,771,113.76 as of December 31, 2023[16] - The total current assets decreased to CNY 747,895,826.33 from CNY 771,442,780.41, reflecting a decline of approximately 3.03%[17] - Total liabilities decreased to CNY 174,161,640.21 from CNY 179,057,693.66, a decline of approximately 2.5%[18] - Current liabilities totaled CNY 171,879,896.10, down from CNY 176,743,449.55, reflecting a decrease of about 2.7%[18] - The company's long-term investments in equity decreased to CNY 103,196,368.37 from CNY 106,264,662.39, a decline of approximately 2.9%[17] Expenses and Costs - Sales expenses increased by 59.93% due to higher marketing and exhibition costs compared to the previous year[10] - Total operating costs for Q1 2024 were ¥34,358,791.33, down 33.9% from ¥51,831,889.26 in Q1 2023[20] - Research and development expenses increased to ¥6,600,012.24 in Q1 2024, compared to ¥5,567,972.60 in Q1 2023[20] Investment and Financing - The company faced a 438.17% decrease in investment income, impacted by market fluctuations due to industry policy reforms[10] - The company reported an investment loss of ¥3,068,294.00 in Q1 2024, compared to a gain of ¥907,316.23 in Q1 2023[20] - The impact of exchange rate changes on cash and cash equivalents was a negative $216,890.98, contrasting with a positive impact of $24,162.34 in the previous period[27] Other Financial Metrics - The weighted average return on equity decreased by 0.48 percentage points to 0.50%[6] - Cash and cash equivalents were reported at CNY 194,841,705.34, down from CNY 267,759,758.00, indicating a decrease of about 27.2%[16] - Accounts receivable slightly decreased to CNY 372,893,082.73 from CNY 384,328,926.60, a reduction of approximately 2.5%[16] - Inventory increased to CNY 81,443,064.78 from CNY 65,155,346.70, representing an increase of about 24.9%[17] - The company reported a significant increase in other receivables, rising to CNY 15,037,067.20 from CNY 10,542,533.71, an increase of approximately 42.5%[17]

Financial Performance - The net profit attributable to the parent company's shareholders for 2023 is CNY 59,999,960.99, with a distributable profit of CNY 245,379,674.89 as of December 31, 2023[6]. - The proposed cash dividend is CNY 1.00 per 10 shares (including tax), totaling CNY 13,600,000, which accounts for 22.67% of the annual net profit attributable to the parent company[6]. - In 2023, the company's operating revenue was CNY 307,559,138.41, a decrease of 4.59% compared to CNY 322,359,785.92 in 2022[23]. - The net profit attributable to shareholders was CNY 59,999,960.99, down 48.13% from CNY 115,681,544.43 in the previous year[23]. - The basic earnings per share decreased to CNY 0.44, a decline of 48.24% from CNY 0.85 in 2022[24]. - The total assets at the end of 2023 were CNY 1,316,771,113.76, reflecting a 9.84% increase from CNY 1,198,844,121.40 in 2022[23]. - The weighted average return on equity was 5.82%, down 6.29 percentage points from 12.11% in 2022[24]. - The cash flow from operating activities showed a net outflow of CNY 35,393,790.08, compared to an inflow of CNY 53,827,755.74 in 2021[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 45,204,051.03, a decrease of 53.27% from CNY 96,730,991.02 in 2022[23]. - The company reported a net asset attributable to shareholders of CNY 1,052,726,420.24 at the end of 2023, an increase of 4.75% from CNY 1,004,966,459.25 in 2022[23]. Risk Management - The report includes a risk statement regarding forward-looking statements, emphasizing that future plans and strategies do not constitute a commitment to investors[7]. - The management discussion and analysis section outlines potential risks that investors should pay attention to[9]. - The company experienced a significant impact on performance due to a slowdown in global economic growth and weakened domestic market demand[23]. - The overall market environment remains challenging, with no significant changes in the industry during the reporting period[40]. - The company recognizes the risk of dependency on its subsidiary Willach for core components of its H series automated dispensing machines, which could impact operations if the partnership deteriorates[126]. - The company faces risks related to customer and supplier concentration, which could adversely affect its profitability if relationships change significantly[128][130]. Strategic Initiatives - The company plans to adapt to the changing market conditions and explore new strategies to enhance performance in the upcoming periods[23]. - The company established a joint venture in Riyadh, Saudi Arabia, with Ajlan & Bros Information Technology Company to promote its products in the Middle East and North Africa, with the first project already operational in a leading private hospital[34]. - The company is strategically expanding into the pharmaceutical retail market by partnering with industry leaders and implementing a "smart pharmacy" model, aiming for nationwide replication[36]. - Increased R&D investment is being directed towards product innovation and technology upgrades to enhance competitiveness in international markets[37]. - The company is actively exploring digital transformation projects in collaboration with the Saudi Ministry of Health, targeting over 2,300 primary healthcare centers[34]. - The company aims to integrate its "smart pharmacy" model with beauty and personal care products, expanding its offerings beyond pharmaceuticals[36]. - The company is focusing on expanding its market through external investments, as indicated by the increase in cash flow from financing activities[70]. Research and Development - The company emphasizes the importance of research and development to maintain its competitive edge in the market[54]. - The company has a well-established R&D system with nearly 20 years of experience in intelligent drug management projects, indicating strong technical innovation capabilities[61]. - Research and development expenses increased by 4.25% to 23.37 million yuan, reflecting the company's commitment to innovation[68]. - The company plans to enhance its R&D capabilities and product development, focusing on machine vision, deep learning, and robotics to lead market demand and achieve innovation[119]. Corporate Governance - The company has established specialized committees under the board to ensure scientific and standardized decision-making[136]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations[139]. - The total remuneration for the board members and senior management during the reporting period amounted to CNY 6,665,289.24[143]. - The company emphasizes investor relations management through various channels to enhance communication and protect investor rights[138]. - The company has not faced any penalties from securities regulatory authorities in the past three years[153]. Shareholder Commitments - The controlling shareholder and actual controller, Dai Jianwei, committed to not transferring or entrusting the management of shares held before the issuance for 36 months after the company's stock listing[187]. - The company will ensure compliance with regulations regarding shareholding changes and lock-up periods during the tenure of its directors and senior management[190]. - The commitments made by shareholders and controllers are designed to stabilize the stock price post-IPO and ensure long-term investment[187]. - The company will implement stock price stabilization measures if the stock price falls below the audited net asset value per share for 20 consecutive trading days[198]. Market Expansion - The company is focusing on expanding its investment in the medical and healthcare sectors, indicating a strategic shift towards high-growth industries[108]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[148]. - The company aims to enhance its software and hardware integration services, particularly in the field of hospital logistics and automation systems[112]. - The company plans to enhance the overall hospital market environment through the promotion of high-quality public hospital development and improved public health service capabilities[46]. Financial Health - Cash and cash equivalents at the end of the period decreased by 26.90% to ¥267,759,758, compared to ¥366,273,999.90 at the end of the previous period[86]. - Accounts receivable increased by 15.45% to ¥384,328,926.60, up from ¥332,887,498.88 in the previous period[87]. - Long-term equity investments rose significantly by 129.57% to ¥106,264,662.39, compared to ¥46,287,612.06 at the end of the previous period[87]. - The company’s total non-current financial assets reached RMB 55.6 million, with a significant increase in fair value[106]. Employee Management - The total number of employees in the parent company and major subsidiaries is 355, with 31 in the parent company and 324 in subsidiaries[164]. - Employee composition includes 62 production personnel, 50 sales personnel, 70 technical personnel, 8 financial personnel, 12 administrative personnel, 27 management personnel, and 126 operational personnel[164]. - The company emphasizes talent development through a structured training program, which includes onboarding, professional skills training, sales training, and management training[167].

证券简称：健麾信息 证券代码：605186 公告编号：2024-014 上海健麾信息技术股份有限公司 与俄罗斯MEDSNAB-GROUP LLC Company签署战略合作协议 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 责任。 重要内容提示： 2024年4月25日，上海健麾信息技术股份有限公司（以下简称"公司" 、"甲方"或"健麾信息"）与俄罗斯MEDSNAB-GROUP LLC Company（以下 简称"MEDSNAB集团"或"乙方"）书面签署了《战略合作协议》。 本战略合作协议为基于未来合作意向而达成的框架性、意向性约定。后 续合作的具体事项和具体金额将以另行签订的合同、协议为准，具体合作 内容和进展尚存在不确定性。 本协议的签订对公司本年度及未来各会计年度财务状况的具体影响存在 不确定性，对公司未来经营业绩的影响需视具体合作项目的推进和实施情 况而定。 一、协议签订的基本情况 （一）协议对方的基本情况 MEDSNAB 集团 成立于1994年，总部位于莫斯科，拥有6家独立运营的公司， 200多名员工。是俄罗斯及独联 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 责任。 重要内容提示： 证券简称：健麾信息 证券代码：605186 公告编号：2024-013 上海健麾信息技术股份有限公司 签署"智慧药店"战略合作协议的进展公告 2024年2月9日，上海健麾信息技术股份有限公司（以下简称"公司"、 "甲方"、"健麾信息"）与某公司（因本次交易涉及保密相关条款，且 出于商业秘密及战略发展的考虑，故豁免披露交易对手方具体名称）签署 了《关于"智慧药店"之战略合作协议》。基于前述战略合作协议约定， 近日，双方签署了《关于"智慧零售项目"业务收购协议》。 交易标的：某公司现有运营的智慧零售项目资产。 本次购买资产事项无需公司董事会及股东大会审议。 本次购买资产事项不构成关联交易，也不构成《上市公司重大资产重组 管理办法》规定的重大资产重组，交易实施不存在重大法律障碍。 一、合同签署情况 2024年2月9日，健麾信息与某公司双方签署了《关于"智慧药店"之战略合作 协议》。具体内容详见公司于2024年02月20日，在上海证券交易所网站（ www.sse. ...

证券代码：605186 证券简称：健麾信息 公告编号：2024-008 上海健麾信息技术股份有限公司 2024 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 1、公司在任董事 8 人，以现场或通讯方式出席 8 人。 2、公司在任监事 3 人，以现场或通讯方式出席 3 人。 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | | 4 | | --- | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 68,418,422 | | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | | 份总数的比例（%） | | 50.3076 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 3、董事会秘书邱泓先生出席了本次会议；其他高管列席了本次会议。 1.本次股东大会采用现场投票和网络投票相结合的表决方式； 2.本次股东大会由公司董事会召集，现场会议由公司董事长戴建伟先生主持 ...

经职工代表大会审议，投票选举陈龙先生（简历详见附件）为公司第三届监 事会职工监事，与公司 2024 年第一次临时股东大会选举的非职工代表监事共同 组成第三届监事会，任期三年，与公司第三届监事会任期一致。 公司第三届监事会职工代表监事人数的比例不低于监事会成员的三分之一， 符合相关法律、法规及《公司章程》的有关规定。上述职工代表监事符合《公司 法》及《公司章程》有关监事任职的资格和条件，将按照法律、法规、规章、规 范性文件及《公司章程》的要求认真履行监事职责。 特此公告。 上海健麾信息技术股份有限公司 关于选举产生第三届监事会职工监事的公告 本公司监事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海健麾信息技术股份有限公司（以下简称"公司"）第二届监事会届满， 根据《中华人民共和国公司法》（以下简称"《公司法》"），《上海证券交易 所上市公司自律监管指引第 1 号——规范运作》等法律、法规、规章、规范性 文件及《公司章程》的规定，公司进行了监事会换届选举。公司第三届监事会由 3名监事组成，其中职工监事1名，非职工代表监事2名。职工监事 ...